EXOSC4

Across TCGA pan-cancer cohorts, EXOSC4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EXOSC4 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EXOSC4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EXOSC4 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where EXOSC4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.263	0.442	.005	49	view →
CCRCC	OS	Median	III,IV	0.607	0.967	.002	28	view →
LSCC	DFS	Median	All	0.973	0.905	.027	9	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
OV	DFS	Median	All	0.863	1.000	.039	4	view →
GBM	OS	Quartile	All	0.613	0.265	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EXOSC4–PDAC (OS)

Open the PDAC breakdown →